Rua Bioscience is transitioning to a direct-to-market distribution model for its medicinal cannabis products in New Zealand. The company will manage all domestic operations from its headquarters in Tairāwhiti.
This strategic shift follows regulatory approval for five new products. These additions significantly expand the company’s domestic product range.
Management expects the new model to improve profit margins and increase responsiveness to telehealth clinics. The decision supports Rua’s mission to create jobs and retain economic value within the Te Tairāwhiti region.
The announcement follows strong sales growth throughout fiscal year 2026. Rua Bioscience anticipates the new distribution structure will sustain this commercial momentum.